| Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort … JL McQuade, CR Daniel, KR Hess, C Mak, DY Wang, RR Rai, JJ Park, ... The Lancet Oncology 19 (3), 310-322, 2018 | 553 | 2018 |
| Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH‐dependent solubility the Achilles heel of targeted therapy? NR Budha, A Frymoyer, GS Smelick, JY Jin, MR Yago, MJ Dresser, ... Clinical Pharmacology & Therapeutics 92 (2), 203-213, 2012 | 360 | 2012 |
| Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152) JA Flygare, M Beresini, N Budha, H Chan, IT Chan, S Cheeti, F Cohen, ... Journal of medicinal chemistry 55 (9), 4101-4113, 2012 | 271 | 2012 |
| Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug–drug interaction potential for molecular targeted agents in clinical development GS Smelick, TP Heffron, L Chu, B Dean, DA West, SL DuVall, BL Lum, ... Molecular pharmaceutics 10 (11), 4055-4062, 2013 | 182 | 2013 |
| A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors C Saura, D Roda, S Roselló, M Oliveira, T Macarulla, JA Pérez-Fidalgo, ... Cancer discovery 7 (1), 102-113, 2017 | 164 | 2017 |
| A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents JG Hurdle, RB Lee, NR Budha, EI Carson, J Qi, MS Scherman, SH Cho, ... Journal of antimicrobial chemotherapy 62 (5), 1037-1045, 2008 | 131 | 2008 |
| Discovery of novel isoxazolines as anti-tuberculosis agents RP Tangallapally, D Sun, N Budha, REB Lee, AJM Lenaerts, B Meibohm, ... Bioorganic & medicinal chemistry letters 17 (23), 6638-6642, 2007 | 123 | 2007 |
| A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens Y Zhang, N Mehrotra, NR Budha, ML Christensen, B Meibohm Clinica chimica acta 398 (1-2), 105-112, 2008 | 108 | 2008 |
| A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer S Cheeti, NR Budha, S Rajan, MJ Dresser, JY Jin Biopharmaceutics & drug disposition 34 (3), 141-154, 2013 | 100 | 2013 |
| Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: frequent utilization in the field of oncology K Yoshida, N Budha, JY Jin Clinical Pharmacology & Therapeutics 101 (5), 597-602, 2017 | 64 | 2017 |
| Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist H Wong, SE Gould, N Budha, WC Darbonne, EE Kadel, H La, B Alicke, ... Drug Metabolism and Disposition 41 (12), 2104-2113, 2013 | 58 | 2013 |
| Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria MR Yago, AR Frymoyer, GS Smelick, LA Frassetto, NR Budha, ... Molecular pharmaceutics 10 (11), 4032-4037, 2013 | 58 | 2013 |
| A simple in vitro PK/PD model system to determine time–kill curves of drugs against Mycobacteria NR Budha, RB Lee, JG Hurdle, RE Lee, B Meibohm Tuberculosis 89 (5), 378-385, 2009 | 54 | 2009 |
| Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs NR Budha, RE Lee, B Meibohm Current medicinal chemistry 15 (8), 809-825, 2008 | 54 | 2008 |
| Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development A Rotte, S Sahasranaman, N Budha Biomedicines 9 (9), 1277, 2021 | 53 | 2021 |
| The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria MR Yago, A Frymoyer, LZ Benet, GS Smelick, LA Frassetto, X Ding, ... The AAPS journal 16, 1358-1365, 2014 | 52 | 2014 |
| Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart … A Baruch, S Mosesova, JD Davis, N Budha, A Vilimovskij, R Kahn, K Peng, ... The American journal of cardiology 119 (10), 1576-1583, 2017 | 51 | 2017 |
| A mechanistic systems pharmacology model for prediction of LDL cholesterol lowering by PCSK9 antagonism in human dyslipidemic populations K Gadkar, N Budha, A Baruch, JD Davis, P Fielder, S Ramanujan CPT: pharmacometrics & systems pharmacology 3 (11), 1-9, 2014 | 49 | 2014 |
| Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents NR Budha, N Mehrotra, R Tangallapally, Rakesh, J Qi, AJ Daniels, ... The AAPS journal 10, 157-165, 2008 | 47 | 2008 |
| Evaluation of cytochrome P450 3A4-mediated drug–drug interaction potential for cobimetinib using physiologically based pharmacokinetic modeling and simulation NR Budha, T Ji, L Musib, S Eppler, M Dresser, Y Chen, JY Jin Clinical pharmacokinetics 55, 1435-1445, 2016 | 38 | 2016 |
